ONA THERAPEUTICS acquired by COLUMBUS VENTURE PARTNERS & MERIEUX EQUITY PARTNERS

Ona Therapeutics is a late-preclinical stage biopharmaceutical company pioneering the development of first-in-class antibody-drug conjugates engineered to overcome tumor resistance and metastatic progression in refractory solid tumors. The company deploys a proprietary, patient-driven target discovery platform that isolates novel tumor-specific antigens and internalizing epitopes, enabling the selective delivery of potent cytotoxic payloads directly into drug-resistant cancer cells while preserving a wide therapeutic index. The asset pipeline is led by ONA-255, a high-affinity ADC targeting advanced breast cancer indications scheduled for imminent clinical trial initiation, followed by ONA-389, a separate preclinical candidate being advanced toward first-in-human studies for colorectal cancer. Operating under an asset-centric corporate model, the entity maintains full worldwide commercial intellectual property rights across its entire pipeline, utilizing specialized contract research organizations to execute its development workflows. The financial profile of the business is characterized by pre-revenue, capital-intensive research operations where economic enterprise value is explicitly driven by regulatory milestone translation, data-readout inflection points, and the validation of human safety and efficacy profiles within highly competitive oncology indications.